Dermata Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Dermata Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2024.
  • Dermata Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$3.17M, a 84.6% decline year-over-year.
  • Dermata Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$11.3M, a 53.8% decline year-over-year.
  • Dermata Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$7.79M, a 18.9% increase from 2022.
  • Dermata Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$9.61M, a 21.6% decline from 2021.
  • Dermata Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$7.9M, a 144% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$11.3M -$3.17M -$1.45M -84.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$9.82M -$2.83M -$1.13M -66.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-13
Q1 2024 -$8.69M -$3.13M -$894K -39.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-13
Q4 2023 -$7.79M -$2.13M -$464K -27.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$7.33M -$1.72M +$705K +29.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$8.04M -$1.7M +$1.03M +37.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-13
Q1 2023 -$9.06M -$2.24M +$546K +19.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-13
Q4 2022 -$9.61M -$1.67M +$883K +34.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$10.5M -$2.42M -$712K -41.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$9.78M -$2.73M -$1.4M -105% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$8.38M -$2.79M -$481K -20.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$7.9M -$2.55M -$2.16M -544% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-21
Q3 2021 -$5.75M -$1.71M -$1.12M -187% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$4.63M -$1.33M -$510K -62.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$4.12M -$2.3M -$884K -62.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$3.24M -$396K Oct 1, 2020 Dec 31, 2020 10-Q 2021-11-15
Q3 2020 -$597K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$822K Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-15
Q1 2020 -$1.42M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.